Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

PURPOSE: The safety and efficacy of ibrutinib, a once-daily Bruton’s tyrosine kinase (BTK) inhibitor, in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was demonstrated in this phase Ib/II study. Extended follow-up up to 8 years is described, representing the longest follow-up for...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff P., Wierda, William, Zhao, Weiqiang, Heerema, Nyla A., Luan, Ying, Liu, Emily A., Dean, James P., O’Brien, Susan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8175012/
https://ncbi.nlm.nih.gov/pubmed/32209572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-2856
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi